Kadcyla (ado-trastuzumab emtansine)

Kadcyla (ado-trastuzumab emtansine) is a targeted cancer therapy used mainly for HER2-positive breast cancer. It combines two components: trastuzumab, a medication that binds to the HER2 protein on cancer cells, and emtansine, a powerful chemotherapy drug attached to it. This design allows the drug to specifically deliver the chemotherapy directly to HER2-positive cancer cells, minimizing damage to healthy tissues. Kadcyla helps slow or stop cancer growth and can be used when cancer has spread or after initial treatments. It offers a more focused treatment option with potentially fewer side effects compared to traditional chemotherapy.